The Nebula antibody development platform, created by Sherbrooke biotech company Immune Biosolutions, located in Espace LABz, will be the subject of a $1.1M research project conducted in collaboration with the Université de Sherbrooke to develop cutting-edge treatments for certain cancers.
Teams led by professors-researchers Fernand Gobeil, Philippe Sarret, and Fernand-Pierre Gendron, associated with the UdeS and the Centre de recherche du CHUS (research centre), will seek to demonstrate the in-vivo efficacy and safety of new therapeutic human antibodies developed in chickens and generated through the Nebula platform, for the purposes of future clinical studies.
Announced at the BIO International Convention’s mass challenge finale in Boston, this R&D project has financial and/or technical support from the Québec Consortium for Drug Discovery (CQDM), the Cancer Research Society, Mathematics of Information Technology and Complex Systems (MITACS), the Ministère de l’Économie, de la Science et de l’Innovation du Québec, and TransferTech Sherbrooke.
» For more details : CQDM
Photo credit : CQDM – Twitter